The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure

Bibliography

• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Hypertension (update): full guideline. Available from: http://www.nice.org.uk/guidance/index.jsp?action=download&o=54727 [Last accessed 6 November 2011]
   Google Scholar
• Williams B, Poulter NR, Brown MJ, British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Dalal JJ, Huang J, The role of beta-blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin 2011;27:1021-33
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9
   PubMed Web of Science ®Google Scholar
• Aursnes I, Osnes JB, Tvete IF, Does atenolol differ from other beta-adrenergic blockers? BMC Clin Pharmacol 2007;7:4
   PubMedGoogle Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009;338:1245-53
   Google Scholar
• Materson BJ. Variability in response to antihypertensive drugs. Am J Med 2007;120:S10-20
   Google Scholar
• Frishman WH, Saunders E. Beta-Adrenergic Blockers. J Clin Hypertens (Greenwich) 2011;13:649-53
   PubMed Web of Science ®Google Scholar
• Richardson DW, Freund J, Gear AS, Effect of propranolol on elevated arterial blood pressure. Circulation 1968;37:534-42
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. department of veterans affairs cooperative study group on antihypertensive agents. Am J Hypertens 1995;8:189-92
   PubMed Web of Science ®Google Scholar
• Kurnik D, Li C, Sofowora GG, Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics 2008;18:895-902
   PubMed Web of Science ®Google Scholar
• Prisant LM, Mensah GA. Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol 1996;36:867-73
   PubMedGoogle Scholar
• Yancy CW, Fowler MB, Colucci WS, Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65
   PubMed Web of Science ®Google Scholar
• Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001;15:17-25
   PubMed Web of Science ®Google Scholar
• Joubert PH, Venter CP, Wellstein A. Ethnic differences in response to beta-blockade: fact or artefact? A study with bisoprolol and propranolol. Eur J Clin Pharmacol 1988;34:363-8
   PubMedGoogle Scholar
• Zhou HH, Koshakji RP, Silberstein DJ, Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989;320:565-70
   PubMed Web of Science ®Google Scholar
• Zhou HH, Wood AJ. Increased suppression of exercise-induced increase in renin by propranolol in Chinese subjects. Clin Pharmacol Ther 1991;50:150-6
   PubMedGoogle Scholar
• Zhou HH, Wood AJ. Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)- and (+)-propranolol. Clin Pharmacol Ther 1990;47:719-23
   PubMedGoogle Scholar
• Zhou HH, Shay SD, Wood AJ. Contribution of differences in plasma binding of propranolol to ethnic differences in sensitivity. Comparison between Chinese and Caucasians. Chin Med J (Engl) 1993;106:898-902
   PubMed Web of Science ®Google Scholar
• Lai ML, Wang SL, Lai MD, Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995;58:264-8
   PubMed Web of Science ®Google Scholar
• Huang CW, Lai ML, Lin MS, Dose-response relationships of propranolol in Chinese subjects with different CYP2D6 genotypes. J Chin Med Assoc 2003;66:57-62
   PubMedGoogle Scholar
• Seedat YK, Stewart-Wynne EG, Reddy J, Experiences with beta-adrenergic blockade drugs in hypertension. S Afr Med J 1973;47:259-62
   PubMed Web of Science ®Google Scholar
• Bristow MR, Ginsburg R, Minobe W, Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11
   PubMed Web of Science ®Google Scholar
• Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993;60:405-30
   PubMed Web of Science ®Google Scholar
• Gauthier C, Leblais V, Kobzik L, The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998;102:1377-84
   PubMed Web of Science ®Google Scholar
• Small KM, Wagoner LE, Levin AM, Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-42
   PubMed Web of Science ®Google Scholar
• Dorn GW II. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev 2010;90:1013-62
   PubMedGoogle Scholar
• Cruikshank JM, McAinsh J. Beta blockers and quality of life. Br J Clin Pract 1992;46:34-8
   PubMedGoogle Scholar
• Cheymol G, Poirier JM, Carrupt PA, Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997;43:563-70
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007;120:10-27
   PubMed Web of Science ®Google Scholar
• Prisant LM. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta(1)-blocker. J Clin Pharmacol 2008;48:225-39
   PubMed Web of Science ®Google Scholar
• Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 1986;8(Suppl 11):S36-40
   Google Scholar
• Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care 2006;29:1167-9
   PubMed Web of Science ®Google Scholar
• Bristow MR. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011;109:1176-94
   PubMed Web of Science ®Google Scholar
• Smart NA, Kwok N, Holland DJ, Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure. Clin Med Insights Cardiol 2011;5:55-66
   PubMedGoogle Scholar
• DeQuattro V, Li D. Sympatholytic therapy in primary hypertension: a user friendly role for the future. J Hum Hypertens 2002;16(Suppl 1):S118-23
   Google Scholar
• Frishman WH. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med 1983;308:940-4
   PubMed Web of Science ®Google Scholar
• Baker JG, Hill SJ, Summers RJ. Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 2011;32:227-34
   PubMed Web of Science ®Google Scholar
• Kaye DM, Smirk B, Williams C, Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003;13:379-82
   PubMedGoogle Scholar
• Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988;1:91-6
   PubMed Web of Science ®Google Scholar
• Prichard BN, Tomlinson B, Walden RJ, The beta-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol 1983;5:S56-62
   Google Scholar
• Walden RJ, Tomlinson B, Graham B, Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers. Br J Clin Pharmacol 1990;30:557-65
   PubMedGoogle Scholar
• Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis 2004;47:11-33
   PubMed Web of Science ®Google Scholar
• Frazier EP, Michel-Reher MB, van Loenen P, Lack of evidence that nebivolol is a beta-adrenoceptor agonist. Eur J Pharmacol 2011;654:86-91
   PubMedGoogle Scholar
• Rozec B, Erfanian M, Laurent K, Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009;53:1532-8
   PubMed Web of Science ®Google Scholar
• El Desoky ES, Derendorf H, Klotz U. Variability in response to cardiovascular drugs. Curr Clin Pharmacol 2006;1:35-46
   PubMedGoogle Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of cardiology foundation task force on clinical expert consensus documents. Circulation 2011;123:2434-506
   PubMed Web of Science ®Google Scholar
• Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 2003;53:814-22
   PubMed Web of Science ®Google Scholar
• Takekuma Y, Takenaka T, Kiyokawa M, Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J Pharm Pharm Sci 2006;9:101-12
   PubMed Web of Science ®Google Scholar
• Takekuma Y, Takenaka T, Yamazaki K, Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. Biol Pharm Bull 2007;30:2146-53
   PubMed Web of Science ®Google Scholar
• Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001;19:215-34, v
   PubMedGoogle Scholar
• Kato Y, Miyazaki T, Kano T, Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci 2009;98:2529-39
   PubMedGoogle Scholar
• Ieiri I, Doi Y, Maeda K, Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 2011; Published online May 18, 2011
   PubMed Web of Science ®Google Scholar
• Schafer-Korting M, Kirch W, Axthelm T, Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther 1983;33:283-8
   PubMedGoogle Scholar
• Ward SA, Walle T, Walle UK, Propranolol metabolism is determined by both mephenytoin and debrisoquin hydroxylase-activities. Clin Pharmacol Ther 1989;45:72-9
   PubMed Web of Science ®Google Scholar
• Hu M, Mak VWL, Chu TTY, Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr Pharm Pers Med 2009;7:1-26
   Google Scholar
• Lennard MS, Jackson PR, Freestone S, The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1984;17:679-85
   PubMed Web of Science ®Google Scholar
• Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996;24:350-5
   PubMed Web of Science ®Google Scholar
• Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006;31:99-109
   PubMed Web of Science ®Google Scholar
• Lefebvre J, Poirier L, Poirier P, The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007;63:575-82
   PubMed Web of Science ®Google Scholar
• Fux R, Morike K, Prohmer AM, Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005;78:378-87
   PubMed Web of Science ®Google Scholar
• Rau T, Heide R, Bergmann K, Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-72
   PubMedGoogle Scholar
• Huang J, Chuang SK, Cheng CL, Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther 1999;65:402-7
   PubMedGoogle Scholar
• Bijl MJ, Visser LE, van Schaik RH, Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009;85:45-50
   PubMed Web of Science ®Google Scholar
• Rau T, Wuttke H, Michels LM, Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009;85:269-72
   PubMed Web of Science ®Google Scholar
• Yuan H, Huang Z, Yang G, Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res 2008;36:1354-62
   PubMed Web of Science ®Google Scholar
• Nozawa T, Taguchi M, Tahara K, Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 2005;46:713-20
   PubMed Web of Science ®Google Scholar
• Goryachkina K, Burbello A, Boldueva S, CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008;64:1163-73
   PubMed Web of Science ®Google Scholar
• Wuttke H, Rau T, Heide R, Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429-37
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, de Boer A, Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 2011;89:662-73
   PubMed Web of Science ®Google Scholar
• Terra SG, Pauly DF, Lee CR, Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005;77:127-37
   PubMed Web of Science ®Google Scholar
• Zineh I, Beitelshees AL, Gaedigk A, Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004;76:536-44
   PubMed Web of Science ®Google Scholar
• Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007;27:874-87
   PubMed Web of Science ®Google Scholar
• Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995;57:518-24
   PubMed Web of Science ®Google Scholar
• Honda M, Nozawa T, Igarashi N, Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol Pharm Bull 2005;28:1476-9
   PubMed Web of Science ®Google Scholar
• Giessmann T, Modess C, Hecker U, CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004;75:213-22
   PubMed Web of Science ®Google Scholar
• Graff DW, Williamson KM, Pieper JA, Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001;41:97-106
   PubMed Web of Science ®Google Scholar
• Sehrt D, Meineke I, Tzvetkov M, Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011;12:783-95
   PubMed Web of Science ®Google Scholar
• Baudhuin LM, Miller WL, Train L, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol 2010;106:402-8
   PubMed Web of Science ®Google Scholar
• Takekuma Y, Takenaka T, Kiyokawa M, Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol Pharm Bull 2007;30:537-42
   PubMed Web of Science ®Google Scholar
• Honda M, Toyoda W, Shimizu T, UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese. Drug Metab Pharmacokinet 2007;22:382-6
   PubMedGoogle Scholar
• Kirch W, Rose I, Klingmann I, Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol 1986;31:59-62
   PubMedGoogle Scholar
• Bristow MR, Murphy GA, Krause-Steinrauf H, An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010;3:21-8
   PubMed Web of Science ®Google Scholar
• Muthumala A, Drenos F, Elliott PM, Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 2008;10:3-13
   PubMed Web of Science ®Google Scholar
• Terra SG, McGorray SP, Wallace MR, Linkage disequilibrium of common beta-1 adrenergic receptor polymorphisms. Clin Pharmacol Ther 2002;71:P70-0
   Google Scholar
• Belfer I, Buzas B, Evans C, Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 2005;13:341-51
   PubMed Web of Science ®Google Scholar
• Mason DA, Moore JD, Green SA, A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999;274:12670-4
   PubMed Web of Science ®Google Scholar
• Levin MC, Marullo S, Muntaner O, The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002;277:30429-35
   Google Scholar
• Green SA, Turki J, Innis M, Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414-19
   PubMed Web of Science ®Google Scholar
• Green SA, Cole G, Jacinto M, A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993;268:23116-21
   PubMed Web of Science ®Google Scholar
• Evans DA, McLeod HL, Pritchard S, Interethnic variability in human drug responses. Drug Metab Dispos 2001;29:606-10
   PubMed Web of Science ®Google Scholar
• Brodde OE. Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol 2008;22:107-25
   PubMed Web of Science ®Google Scholar
• Leineweber K, Heusch G. Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases. Br J Pharmacol 2009;158:61-9
   PubMed Web of Science ®Google Scholar
• Hahntow IN, Koopmans RP, Michel MC. The beta2-adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? J Hypertens 2006;24:1003-7
   PubMedGoogle Scholar
• Thomsen M, Dahl M, Tybjaerg-Hansen A, Beta(2)-adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals. J Intern Med 2012;271:305-14
   PubMed Web of Science ®Google Scholar
• Lobmeyer MT, Wang L, Zineh I, Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics 2011;21:42-9
   PubMed Web of Science ®Google Scholar
• Petersen M, Andersen JT, Hjelvang BR, Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol 2011;71:556-65
   PubMedGoogle Scholar
• Klenke S, Kussmann M, Siffert W. The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenet Genomics 2011;21:594-606
   PubMedGoogle Scholar
• Bagos PG, Elefsinioti AL, Nikolopoulos GK, The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14,094 cases and 17,760 controls. J Hypertens 2007;25:487-500
   PubMed Web of Science ®Google Scholar
• Jia H, Hingorani AD, Sharma P, Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999;34:8-14
   PubMed Web of Science ®Google Scholar
• Kurnik D, Cunningham AJ, Sofowora GG, GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics 2009;10:1581-7
   PubMed Web of Science ®Google Scholar
• Rafiq S, Anand S, Roberts R. Genome-wide association studies of hypertension: have they been fruitful? J Cardiovasc Transl Res 2010;3:189-96
   PubMedGoogle Scholar
• Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep 2010;12:17-25
   PubMed Web of Science ®Google Scholar
• Levy D, Ehret GB, Rice K, Genome-wide association study of blood pressure and hypertension. Nat Genet 2009;41:677-87
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Johnson T, Gateva V, Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009;41:666-76
   PubMed Web of Science ®Google Scholar
• Kato N, Takeuchi F, Tabara Y, Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011;43:531-8
   PubMed Web of Science ®Google Scholar
• Dupuis J, Langenberg C, Prokopenko I, New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-16
   PubMed Web of Science ®Google Scholar
• Rorsman P, Bokvist K, Ammala C, Activation by adrenaline of a low-conductance G protein-dependent K+ channel in mouse pancreatic B cells. Nature 1991;349:77-9
   PubMed Web of Science ®Google Scholar
• Prichard BN, Gillam PM. Use of propranolol (Inderal) in treatment of hypertension. Br Med J 1964;2:725-7
   PubMed Web of Science ®Google Scholar
• Jia H, Sharma P, Hopper R, Beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens 2000;18:687-93
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy KM, Fu B, Dickerson C, The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000;99:233-8
   PubMed Web of Science ®Google Scholar
• Johnson JA, Zineh I, Puckett BJ, Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003;74:44-52
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZQ, Tan ZR, Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003;74:372-9
   PubMed Web of Science ®Google Scholar
• Sofowora GG, Dishy V, Muszkat M, A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003;73:366-71
   PubMed Web of Science ®Google Scholar
• Beitelshees AL, Zineh I, Yarandi HN, Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J 2006;6:174-8
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZQ, Yu BN, Beta(1)-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006;80:23-32
   PubMed Web of Science ®Google Scholar
• Sasaguri T, Shiraishi F, Yoshihara T, Beta(1)-Adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects. J Pharmacol Sci 2011;115:490-9
   PubMed Web of Science ®Google Scholar
• Filigheddu F, Reid JE, Troffa C, Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004;4:154-60
   PubMed Web of Science ®Google Scholar
• Filigheddu F, Argiolas G, Degortes S, Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 2010;11:319-25
   PubMed Web of Science ®Google Scholar
• Karlsson J, Lind L, Hallberg P, Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004;27:347-50
   PubMed Web of Science ®Google Scholar
• Suonsyrja T, Donner K, Hannila-Handelberg T, Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics 2010;20:342-5
   PubMed Web of Science ®Google Scholar
• Lee J, Aziz H, Liu L, Beta(1)-adrenergic receptor polymorphisms and response to beta-blockade in the African-American study of kidney disease and hypertension (AASK). Am J Hypertens 2011;24:694-700
   PubMed Web of Science ®Google Scholar
• Pacanowski MA, Gong Y, Cooper-Dehoff RM, Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008;84:715-21
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT, Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23
   PubMed Web of Science ®Google Scholar
• Bristow MR, Gilbert EM, Abraham WT, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302
   PubMed Web of Science ®Google Scholar
• Investigators TR. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7
   PubMed Web of Science ®Google Scholar
• Terra SG, Hamilton KK, Pauly DF, Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005;15:227-34
   PubMedGoogle Scholar
• Chen L, Meyers D, Javorsky G, Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 2007;17:941-9
   PubMed Web of Science ®Google Scholar
• Mialet Perez J, Rathz DA, Petrashevskaya NN, Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003;9:1300-5
   PubMed Web of Science ®Google Scholar
• de Groote P, Helbecque N, Lamblin N, Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005;15:137-42
   PubMed Web of Science ®Google Scholar
• Metra M, Covolo L, Pezzali N, Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 2010;24:49-60
   PubMed Web of Science ®Google Scholar
• Troncoso R, Moraga F, Chiong M, Gln(27)–>Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol 2009;104:374-8
   PubMed Web of Science ®Google Scholar
• Lobmeyer MT, Gong Y, Terra SG, Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007;17:277-82
   PubMed Web of Science ®Google Scholar
• Cresci S, Kelly RJ, Cappola TP, Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009;54:432-44
   PubMed Web of Science ®Google Scholar
• Biolo A, Clausell N, Santos KG, Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 2008;102:726-32
   PubMed Web of Science ®Google Scholar
• Borjesson M, Magnusson Y, Hjalmarson A, A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000;21:1853-8
   PubMed Web of Science ®Google Scholar
• White HL, de Boer RA, Maqbool A, An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003;5:463-8
   PubMed Web of Science ®Google Scholar
• Shin J, Lobmeyer MT, Gong Y, Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 2007;99:250-5
   PubMed Web of Science ®Google Scholar
• Sehnert AJ, Daniels SE, Elashoff M, Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008;52:644-51
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Levin MC, Eggertsen R, Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005;78:221-31
   PubMed Web of Science ®Google Scholar
• Liggett SB, Mialet-Perez J, Thaneemit-Chen S, A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103:11288-93
   PubMed Web of Science ®Google Scholar
• Liggett SB, Cresci S, Kelly RJ, A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008;14:510-17
   PubMed Web of Science ®Google Scholar
• Littlejohn MD, Palmer BR, Richards AM, Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail 2008;10:55-9
   PubMed Web of Science ®Google Scholar
• Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Churchill Livingstone; Edinburgh, London, Madrid, Melbourne, New York, Tokyo; 1988
   Google Scholar
• Christian H, Bertera FM, Mayer MA, Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 2010;6:199-211
   PubMed Web of Science ®Google Scholar
• Bonow RO, Mann DL, Zipes DP, Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, Philadelphia; 2011
   Google Scholar
• Stringer RA, Strain-Damerell C, Nicklin P, Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 2009;37:1025-34
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Heesch C, Bauer S, Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004;76:302-12
   PubMed Web of Science ®Google Scholar
• Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 2011;89:366-78
   PubMed Web of Science ®Google Scholar
• Mahesh Kumar KN, Ramu P, Rajan S, Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population. J Cardiovasc Pharmacol 2008;52:459-66
   PubMed Web of Science ®Google Scholar
• Liu ZQ, Liu J, Xiang ZH, Distributive characteristics of Ser49Gly and Gly389Arg genetic polymorphisms of beta1-adrenoceptor in Chinese Han and Dai populations. Acta Pharmacol Sin 2006;27:254-8
   PubMed Web of Science ®Google Scholar
• Maxwell TJ, Ameyaw MM, Pritchard S, Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med 2005;16:573-80
   PubMed Web of Science ®Google Scholar
• Thomas GN, Tomlinson B, Chan JC, The Trp64Arg polymorphism of the beta3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome. Int J Obes Relat Metab Disord 2000;24:545-51
   PubMed Web of Science ®Google Scholar
• Chen QJ, Lu L, Jin C, Insertion/insertion genotype of alpha(2B)-adrenergic receptor gene polymorphism is associated with silent myocardial ischemia in patients with type 2 diabetes mellitus. Clin Biochem 2010;43:1201-4
   PubMed Web of Science ®Google Scholar
• Rosskopf D, Manthey I, Siffert W. Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein beta3 subunit. Pharmacogenetics 2002;12:209-20
   PubMedGoogle Scholar
• de Groote P, Helbecque N, Lamblin N, Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail 2004;6:17-21
   PubMed Web of Science ®Google Scholar